Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Med Virol ; 94(1): 291-297, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34491575

RESUMEN

Due to current advances and growing experience in the management of coronavirus Disease 2019 (COVID-19), the outcome of COVID-19 patients with severe/critical illness would be expected to be better in the second wave compared with the first wave. As our hospitalization criteria changed in the second wave, we aimed to investigate whether a favorable outcome occurred in hospitalized COVID-19 patients with only severe/critical illness. Among 642 laboratory-confirmed hospitalized COVID-19 patients in the first wave and 1121 in the second wave, those who met World Health Organization (WHO) definitions for severe or critical illness on admission or during follow-up were surveyed. Data on demographics, comorbidities, C-reactive protein (CRP) levels on admission, and outcomes were obtained from an electronic hospital database. Univariate analysis was performed to compare the characteristics of patients in the first and second waves. There were 228 (35.5%) patients with severe/critical illness in the first wave and 681 (60.7%) in the second wave. Both groups were similar in terms of age, gender, and comorbidities, other than chronic kidney disease. Median serum CRP levels were significantly higher in patients in the second wave compared with those in the first wave [109 mg/L (interquartile range [IQR]: 65-157) vs. 87 mg/L (IQR: 39-140); p < 0.001]. However, intensive care unit admission and mortality rates were similar among the waves. Even though a lower mortality rate in the second wave has been reported in previous studies, including all hospitalized COVID-19 patients, we found similar demographics and outcomes among hospitalized COVID-19 patients with severe/critical illness in the first and second wave.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , COVID-19/mortalidad , Cuidados Críticos/estadística & datos numéricos , Índice de Severidad de la Enfermedad , Anciano , Amidas/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Azitromicina/uso terapéutico , Proteína C-Reactiva/análisis , COVID-19/epidemiología , COVID-19/patología , Comorbilidad , Combinación de Medicamentos , Enoxaparina/uso terapéutico , Femenino , Mortalidad Hospitalaria , Hospitalización/estadística & datos numéricos , Humanos , Hidroxicloroquina/uso terapéutico , Proteína Antagonista del Receptor de Interleucina 1/uso terapéutico , Lopinavir/uso terapéutico , Masculino , Metilprednisolona/uso terapéutico , Persona de Mediana Edad , Pirazinas/uso terapéutico , Estudios Retrospectivos , Ritonavir/uso terapéutico , SARS-CoV-2 , Resultado del Tratamiento , Turquía/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA